The COVID-19 Health Risk Framework for Work Accommodations was developed by a local expert group to help inform decision making.

OMA COVID Clearance Attestation Form, patients can be directed to this in the Patient Resources section of this website.

The OCFP has some additional condition specific recommendations not specifically mentioned in the above table:

Cancer: Expert opinion also suggests those in active treatment (chemo, radiation, immunotherapy, recovering from surgery) stay home as much as possible to minimize the risk of exposure, and practise physical distancing when needing to go out. This would likely preclude in-person work.

Inflammatory Bowel Disease: The guidance is to work from home or to school at home if new diagnosis, severe active inflammation, malnutrition, prednisone >20 mg per day (Crohn’s and Colitis Canada). See this letter for the workplace.

Patients on immunosuppressants: For all transplant recipients taking immunosuppressants, as well as patients on chronic prednisone >20 mg per day, it is likely best that they avoid a workplace setting.

DMARDS do NOT appear to be associated with increased risk of serious COVID-19 related disease (Crohn’s and Colitis Canada). Patients should discuss with their rheumatologist the extent to which their medications increase their risk and the degree of risk of transmission based on their job duties (Arthritis Research Canada).

Primary care providers who are asymptomatic and have returned from travel outside of the country or from travel to an area inside the country with an elevated rate of COVID-19, in the last 14 days and/or have had unprotected exposure to a person with COVID-19 and have been identified critical to operations in their organization, should refer to the How to Self-isolate while Working fact sheet and the Quick Reference Sheet Public Health Guidance on Testing and Clearance available on the MOH COVID-19 website

See also: COVID-19 Quick Reference Public Health Guidance on Testing and Clearance

Leave a Reply